Oncopeptides AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ONCO.ST research report →
Companywww.oncopeptides.com/sv
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
- CEO
- Sofia Heigis
- IPO
- 2017
- Employees
- 80
- HQ
- Stockholm, SE
Price Chart
Valuation
- Market Cap
- $413.53M
- P/E
- -2.21
- P/S
- 4.96
- P/B
- 6.36
- EV/EBITDA
- -1.64
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 96.57%
- Op Margin
- -247.60%
- Net Margin
- -265.27%
- ROE
- 2083.70%
- ROIC
- -95.72%
Growth & Income
- Revenue
- $71.12M · 124.72%
- Net Income
- $-249,585,000 · 12.31%
- EPS
- $-1.10 · 35.67%
- Op Income
- $-228,824,000
- FCF YoY
- 14.46%
Performance & Tape
- 52W High
- $6.96
- 52W Low
- $1.25
- 50D MA
- $1.45
- 200D MA
- $3.64
- Beta
- -1.42
- Avg Volume
- 5.15M
Get TickerSpark's AI analysis on ONCO.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ONCO.ST Coverage
We haven't published any research on ONCO.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ONCO.ST Report →